Samsung Biologics 4th plant.

On the 22nd, Samsung Biologics announced that it will establish a newly partitioned company, Samsung Bioepis Holdings (tentative name), by simply partitioning off its subsidiary Samsung Bioepis. The company stated that the newly partitioned company Samsung Bioepis Holdings aims for management of the subsidiary and new investments.

The key is to partition Samsung Biologics, which focuses on contract development and manufacturing organization (CDMO) business, from Samsung Bioepis, which operates in the biosimilar (generic biologics) sector.

Previously, Samsung Group established Samsung Biologics and Samsung Bioepis by partitioning the institutional sector of Samsung Electronics' bio and chemical sectors. Samsung Bioepis is a joint venture established in 2012 between Samsung Biologics and U.S. company Biogen, initially with Samsung Biologics holding 85% equity and Biogen 15%. Later, in 2022, Samsung Biologics acquired all the equity held by Biogen, making Samsung Bioepis a wholly owned subsidiary.

Through this partitioning, Samsung Biologics will emerge as a pure CDMO company. Samsung Bioepis Holdings, established as a pure holding company, is expected to fully integrate Samsung Bioepis, a biosimilars corporation, as a subsidiary in the future.

The company stated that this is to establish an efficient governance structure capable of quick and professional decision-making suitable for the characteristics and strategies of each business.

The partitioning date is set for midnight on October 1st. However, the company may change the partitioning date.